Regimen for the administration of rifamycin-class antibiotics

Details Regimen for the administration of rifamycin-class antibiotics Regimen for the administration of rifamycin-class antibiotics

2004-09-23

2010-10-26

Padmanabhan, Sreeni (Department: 1627)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S229500, C514S252130, C514S291000

Reexamination Certificate

active

07820652

ABSTRACT:
The invention features an ascending dose regimen for the administration of rifamycin-class antibiotics. The dosing regimen can be used to treat bacterial infections and diseases related to infection.

REFERENCES:
patent: 3301753 (1967-01-01), Sensi et al.
patent: 3338888 (1967-08-01), Bickel et al.
patent: 3342810 (1967-09-01), Maggi et al.
patent: 3884673 (1975-05-01), Olin
patent: 3923791 (1975-12-01), Celmer
patent: 3976765 (1976-08-01), Nachtigal
patent: 4005077 (1977-01-01), Bickel et al.
patent: 4017481 (1977-04-01), Marsili et al.
patent: 4086225 (1978-04-01), Marsili et al.
patent: 4164499 (1979-08-01), Rossetti et al.
patent: 4165317 (1979-08-01), Rossetti et al.
patent: 4188321 (1980-02-01), Maggi et al.
patent: 4219478 (1980-08-01), Marsili et al.
patent: 4226765 (1980-10-01), Marsili et al.
patent: 4305941 (1981-12-01), Marsili et al.
patent: 4341785 (1982-07-01), Marchi et al.
patent: 4551450 (1985-11-01), Traxler
patent: 4585589 (1986-04-01), Malabarba et al.
patent: 4681938 (1987-07-01), Traxler
patent: 4690919 (1987-09-01), Yamane et al.
patent: 4859661 (1989-08-01), Kano et al.
patent: 4876258 (1989-10-01), Kump et al.
patent: 4983602 (1991-01-01), Yamane et al.
patent: 5003070 (1991-03-01), Kump et al.
patent: 5352679 (1994-10-01), Ferrieri et al.
patent: 5547683 (1996-08-01), Yano et al.
patent: 5786349 (1998-07-01), Yamashita et al.
patent: 5786350 (1998-07-01), Occelli et al.
patent: 5981522 (1999-11-01), Yamashita et al.
patent: 6316433 (2001-11-01), Rose et al.
patent: 6486161 (2002-11-01), Fujii et al.
patent: 6566354 (2003-05-01), Rose et al.
patent: 2003/0165457 (2003-09-01), Martin
patent: 2003/0203903 (2003-10-01), Rose et al.
patent: 2003/0236265 (2003-12-01), Sayada
patent: 2004/0014750 (2004-01-01), Michaelis et al.
patent: 2004/0034021 (2004-02-01), Michaelis et al.
patent: 2004/0077533 (2004-04-01), Sayada
patent: 2004/0106590 (2004-06-01), Eisenstein
patent: 2004/0126414 (2004-07-01), Michaelis
patent: 2004/0157840 (2004-08-01), Cabana et al.
patent: 2004/0176404 (2004-09-01), Sayada
Coates et al. Nature Reviews: Drug Discovery, 2002, vol. 1, pp. 895-910.
“Rifalazil PathoGenesis Plans Phase II Studies,”R&D Focus Drug News(1997).
Dietze et al., “Safety and Bactericidal Activity of Rifalazil in Patients with Pulmonary Tuberculosis,”Antimicrobial Agents and Chemotherapy45(7):1972 (2001).
Dhople AM, “In Vivo Susceptibility of Mycobacterium Ulcerans to KRM-1648, A New Benzoxazinorifamycin, in Comparison with Rifampicin,”Arzneimittelforschung51(6):501 (2001).
Hosoe et al., “Pharmacokinetics of KRM-1648, a New Benzoxazinorifamycin, in Rats and Dogs,”Antimicrobial Agents and Chemotherapy40(12):2749 (1996).
Kissling et al., “Parenteral Rifampicin in Tuberculous and Severe Non-Mycobacterial Infections,”Chemotherapy28:229 (1982).
Martinez et al., “Hypersensitivity Reactions to Rifampin. Pathogenetic Mechanisms, Clinical Manifestations, Management Strategies, and Review of the Anaphylactic-like Reactions,”Mayo J. Medicine(Baltimore) 78(6):361 (1999).
Yamamoto et al., “In Vitro Bactericidal and In Vivo Therapeutic Activities of a New Rifamycin Derivative, KRM-1648, Against Mycobacterium Tuberculosis,”Antimicrobial Agents and Chemotherapy40(2):426 (1996).
Yamamoto et al., “Activity of KRM-1648 Alone or in Combination with Both Ethambutol and Kanamycin or Clarithromycin Against Mycobacterium Intracellulare Infections in Beige Mice,”Antimicrobial Agents and Chemotherapy40(2):429 (1996).

Affiliated with

Also associated with

Rating

Regimen for the administration of rifamycin-class antibiotics does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Regimen for the administration of rifamycin-class antibiotics, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Regimen for the administration of rifamycin-class antibiotics will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4189302